Compare Viatris Inc (VTRS) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Western Union Co — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Western Union Co trades at $8.9 (market cap $2.71B). The key difference: Viatris Inc is far larger — about 7.3× Western Union Co's market cap, and Western Union Co pays the higher dividend (10.85%). Which is the better fit depends on your goals.
| VTRS | WU | |
|---|---|---|
Market Cap | $19.79B | $2.71B |
Sector | Health | Technology |
52-Week High | $17.39 | $10.28 |
52-Week Low | $8.74 | $7.04 |
Enterprise Value | $32.00B | $2.40B |
Dividend Yield | 2.83% | 10.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Western Union (WU) trades at $8.46, down 4.73% on the day, with a bullish technical signal but mixed sentiment. The stock shows attractive valuation metrics with a P/E of 6.37 and P/S of 0.69, supported by strong profitability including a 10.88% net margin and 47.66% ROE. Recent developments include a partnership with Total Wireless and pending acquisition of Intermex, while Q1 2026 earnings missed expectations. Cash flow trends show volatility, with 2025 net cash flow negative $469.2 million.
Outlook remains cautious due to declining revenue trends and mixed analyst ratings, with 58% hold recommendations. The 11% dividend yield offers income appeal, but competitive pressures and execution risks on digital transformation pose challenges. Near-term catalyst is Q2 2026 results on July 30, 2026, with consensus EPS estimate of $0.43.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
